Trial Profile
A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Cisplatin; Etoposide; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 09 Feb 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 03 Aug 2023 Planned End Date changed from 30 Jun 2023 to 31 Dec 2023.
- 30 Jan 2023 Planned End Date changed from 31 Dec 2022 to 30 Jun 2023.